ArticlePLoS pathogens2021
Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab.
Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- A bibliometric and text-mining analysis of lipidomics and metabolomics in human disease.Frontiers in physiology · 2026Pooled it
- Machine learning and data-driven inverse modeling of metabolomics unveil key processes of active aging.NPJ systems biology and applications · 2025Trial
- Interleukin 6 Blockade With Tocilizumab Diminishes Indices of Inflammation That Are Linked to Mortality in Treated Human Immunodeficiency Virus Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Network-based integration of metabolomics data from large-scale repositories.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Recent Trends in Metabolomics by NMR Spectroscopy.Angewandte Chemie (International ed. in English) · 2026Review
- Host metabolic responses to SARS-CoV-2 and influenza viruses: parallels and contrasts.Metabolomics : Official journal of the Metabolomic Society · 2026Review
- Metabolic Reprogramming in Respiratory Viral Infections: A Focus on SARS-CoV-2, Influenza, and Respiratory Syncytial Virus.Biomolecules · 2025Review
- PINLYP-mediated phospholipid metabolism reprogramming contributes to chronic herpesvirus infection.PLoS pathogens · 2025Article
- Metabolomic and lipoproteomic differences and similarities between COVID-19 and other types of pneumonia.Scientific reports · 2025Article
- COVID-19: A Systematic Review of Metabolomics Data and Predicting Potential Biomarkers Based on Pathway Analysis.Tanaffos · 2025Review
- Time-series metabolomic profiling of SARS-CoV-2 infection: Possible prognostic biomarkers in patients in the ICU by ¹H-NMR analysis.PloS one · 2025Article
- Metabolomic profiling of COVID-19 using serum and urine samples in intensive care and medical ward cohorts.Scientific reports · 2024Article
- Article
- Metabolomic profiling of maternal plasma identifies inverse associations of acetate and urea with anti-SARS-CoV-2 antibody titers following COVID-19 vaccination during pregnancy.Journal of molecular medicine (Berlin, Germany) · 2024Article
- Comparing plasma and skin imprint metabolic profiles in COVID-19 diagnosis and severity assessment.Journal of molecular medicine (Berlin, Germany) · 2024Article
- CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome.Frontiers in pharmacology · 2024Article
- Article
- The biomarkers' landscape of post-COVID-19 patients can suggest selective clinical interventions.Scientific reports · 2023Article
- COVID-19: A complex disease with a unique metabolic signature.PLoS pathogens · 2023Article
- Stratification of hypertension and SARS-CoV-2 infection by quantitative NMR spectroscopy of human blood serum.Communications medicine · 2023Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current pandemic emergence of novel coronavirus disease (COVID-19) poses a relevant threat to global health. SARS-CoV-2 infection is characterized by a wide range of clinical manifestations, ranging from absence of symptoms to severe forms that need intensive care treatment. Here, plasma-EDTA samples of 30 patients compared with age- and sex-matched controls were analyzed via untargeted nuclear magnetic resonance (NMR)-based metabolomics and lipidomics. With the same approach, the effect of tocilizumab administration was evaluated in a subset of patients. Despite the heterogeneity of the clinical symptoms, COVID-19 patients are characterized by common plasma metabolomic and lipidomic signatures (91.7% and 87.5% accuracy, respectively, when compared to controls). Tocilizumab treatment resulted in at least partial reversion of the metabolic alterations due to SARS-CoV-2 infection. In conclusion, NMR-based metabolomic and lipidomic profiling provides novel insights into the pathophysiological mechanism of human response to SARS-CoV-2 infection and to monitor treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.